MedCap acquires and develops profitable, market-leading niche companies in the Nordic life science industry that have the potential to grow internationally. The group conducts operations in three areas: MedTech, Specialty Pharma and Pharma Trading
During the shortened fiscal year 1 May- 31 December 2017, the MedCap group exhibited annual sales of approximately SEK 533 million and EBITDA of SEK 42 million, and had approximately 330 employees. The group is listed on the Small Cap list of Nasdaq Stockholm.